SAN FRANCISCO (GenomeWeb) – Veracyte CEO Bonnie Anderson said this week that the company is working on two new products in the realm of thyroid and lung cancer diagnostics that would expand on the existing Afirma and Percepta tests it currently markets in those areas.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.